U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C7H5O3.Mg.4H2O
Molecular Weight 370.5923
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM SALICYLATE

SMILES

c1ccc(c(c1)C(=O)O)O.c1ccc(c(c1)C(=O)[O-])[O-].[Mg+2].O.O.O.O

InChI

InChIKey=NBQBEWAYWAMLJJ-UHFFFAOYSA-L
InChI=1S/2C7H6O3.Mg.4H2O/c2*8-6-4-2-1-3-5(6)7(9)10;;;;;/h2*1-4,8H,(H,9,10);;4*1H2/q;;+2;;;;/p-2

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mg
Molecular Weight 24.3051
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
2001
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.
2001
Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.
2001 Apr
Cyanide-resistant alternative respiration is strictly correlated to intracellular peroxide levels in Acremonium chrysogenum.
2001 Apr
[Principal constituents from flowering aerial parts of wild pansy].
2001 Apr
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death.
2001 Apr
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.
2001 Apr
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane.
2001 Apr
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR.
2001 Apr
Nitric oxide: comparative synthesis and signaling in animal and plant cells.
2001 Apr
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.
2001 Apr
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
2001 Apr 13
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
2001 Apr 30
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Hereditary palmoplantar keratoderma (four cases in three generations).
2001 Feb
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.
2001 Feb
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus.
2001 Feb 28
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.
2001 Feb 28
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.
2001 Jan
Pathogen-induced expression of plant ATP: citrate lyase.
2001 Jan 19
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
2001 Jan-Feb
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3.
2001 Jul 13
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.
2001 Jun 1
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.
2001 Mar
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid.
2001 Mar
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.
2001 Mar
Interference by bilirubin in salicylate measurement.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Identification of free radicals produced during phacoemulsification.
2001 Mar
Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations.
2001 Mar 23
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes.
2001 Mar 23
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.
2001 May
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.
2001 May
Acanthoamoeba attachment to contact lenses.
2001 May
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle.
2001 May 1
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen.
2001 May 11
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
2001 May 8
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:53 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:53 UTC 2021
Record UNII
41728CY7UX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM SALICYLATE
INCI   MI   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
MAGNESIUM SALICYLATE [VANDF]
Common Name English
MAGNESIUM SALICYLATE TETRAHYDRATE [MI]
Common Name English
MOMENTUM
Brand Name English
MAGNESIUM SALICYLATE [USP MONOGRAPH]
Common Name English
MAGNESIUM SALICYLATE (1:2), TETRAHYDRATE
Common Name English
MAGNESIUM SALICYLATE [USP-RS]
Common Name English
MAGNESIUM SALICYLATE [WHO-DD]
Common Name English
MAGNESIUM SALICYLATE [INCI]
Common Name English
MAGNESIUM SALICYLATE TETRAHYDRATE
Systematic Name English
BACKACHE CAPLETS
Brand Name English
MAGNESIUM, BIS(2-(HYDROXY-.KAPPA.O)BENZOATO-.KAPPA.O)-, HYDRATE (1:4), (T-4)-
Systematic Name English
BAYER SELECT BACKACHE
Brand Name English
Classification Tree Code System Code
DSLD 3106 (Number of products:3)
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2106755
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
DRUG BANK
DB01397
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
PUBCHEM
5282387
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
NCI_THESAURUS
C66050
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
RXCUI
253186
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
CAS
18917-95-8
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
RXCUI
52364
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
ALTERNATIVE
USP_CATALOG
1374306
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M7019
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY Merck Index
EVMPD
SUB14444MIG
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
MESH
C496892
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
DRUG CENTRAL
4510
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
FDA UNII
41728CY7UX
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
EPA CompTox
18917-95-8
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY